N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=10 Tolvaptan for Ascites in Cirrhotic Patients
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Phase 4 N=29 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 2 N=6 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 3 N=162 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
N/A N=136 Improving Performance of Paracentesis in Medical Residency Training
Ascites · Cirrhosis
Primary: Score Out of Total Possible 25 on a Likert Scale. — 21; 21; 20 units on a Likert scale (maximum is 25)
Phase 3 N=51 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
Cirrhosis
Primary: Body Weight — -0.76; -2.97; -0.05 Kg
Phase 3 N=40 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
Cirrhosis
Primary: Body Weight — -1.14; -1.37 kg
Phase 3 N=33 Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Median Time to Paracentesis — 28; 14 days — p=0.17
Phase 4 N=178 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
N/A N=407 Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Cirrhosis of Liver
Primary: Detection Rate of Patients With HCC — 27.9; 86.0 percentage of HCC detected on each exam — p=<0.01
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 2 N=16 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms
Primary: Percentage of Participants With a Repeat Paracentesis Response (RPR) — 62.5 percentage of participants
Phase 3 N=400 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Carcinoma, Hepatocellular
Primary: Overall Survival — 8.7; 6.8 months
N/A N=105 HepaSphere™ Microspheres Prospective Registry
Metastatic Colorectal Cancer
Primary: Overall Survival — 19 months
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 2 N=30 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Phase 2 N=263 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Cirrhosis · Portal Hypertension · Non-alcoholic Steatohepatitis
Primary: Mean Change in Hepatic Venous Pressure Gradient (HVPG) — -0.48; -0.81; -0.70; -0.18 mmHg
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=100 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
Hepatocellular Carcinoma · Metastasis · Invasion
Primary: Overall Survival — 333; 290 days — p=0.4593
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM